BRPI0713421A2 - Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero - Google Patents

Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero Download PDF

Info

Publication number
BRPI0713421A2
BRPI0713421A2 BRPI0713421-5A BRPI0713421A BRPI0713421A2 BR PI0713421 A2 BRPI0713421 A2 BR PI0713421A2 BR PI0713421 A BRPI0713421 A BR PI0713421A BR PI0713421 A2 BRPI0713421 A2 BR PI0713421A2
Authority
BR
Brazil
Prior art keywords
formulation
antibody
methods
liofolized
liophilization
Prior art date
Application number
BRPI0713421-5A
Other languages
English (en)
Inventor
Agarkhed Meera
Srivastava Arvind
Goldstein Joel
Original Assignee
Imclone Systems Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Incorporated filed Critical Imclone Systems Incorporated
Publication of BRPI0713421A2 publication Critical patent/BRPI0713421A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

FORMULAçãO LIOFILIZADA, FORMULAçãO AQUOSA ADEQUADA PARA A LIOFILIZAçãO, E, MéTODOS PARA ESTABILIZAR UM ANTICORPO E PARA TRATAR UM MAMìFERO. Em uma forma de realização, a presente invenção fornece uma formulação liofilizada estável que compreende um anticorpo anti-EGFR, preferivelmente cetuximab; ácido lactobiónico; e um tampão, preferivelmente histidina. Em uma forma de realização preferida, a presente invenção fornece uma formulação liofilizada estável que compreende cerca de 50 mg/ml a cerca de 140 mg/ml de ERBITUX?, cerca de 0,125% de ácido lactobiónico, cerca de 25 mM de tampão de histidina em um pH de cerca de 6,0, cerca de 0,005% de Tween 80 e cerca de 1,875% de glicina.
BRPI0713421-5A 2006-06-14 2007-06-13 Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero BRPI0713421A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81395806P 2006-06-14 2006-06-14
US60/813958 2006-06-14
PCT/US2007/071119 WO2007147001A2 (en) 2006-06-14 2007-06-13 Lyophilized formulations of anti-egfr antibodies

Publications (1)

Publication Number Publication Date
BRPI0713421A2 true BRPI0713421A2 (pt) 2012-03-13

Family

ID=38832820

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0713421-5A BRPI0713421A2 (pt) 2006-06-14 2007-06-13 Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero

Country Status (18)

Country Link
US (1) US20100158925A1 (pt)
EP (1) EP2029163A4 (pt)
JP (1) JP2009540015A (pt)
KR (1) KR20090021298A (pt)
CN (1) CN101466404A (pt)
AU (1) AU2007260769A1 (pt)
BR (1) BRPI0713421A2 (pt)
CA (1) CA2654794A1 (pt)
CR (1) CR10493A (pt)
EA (1) EA200870538A1 (pt)
EC (1) ECSP088962A (pt)
IL (1) IL195794A0 (pt)
MA (1) MA30515B1 (pt)
MX (1) MX2008015852A (pt)
NO (1) NO20085131L (pt)
TN (1) TNSN08511A1 (pt)
WO (1) WO2007147001A2 (pt)
ZA (1) ZA200810456B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7705132B2 (en) * 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
CN101716343A (zh) * 2008-10-09 2010-06-02 哈药集团生物工程有限公司 一种单克隆抗体的冻干制剂
FR2944448B1 (fr) * 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
PL3721904T3 (pl) * 2009-11-20 2022-01-31 Biocon Limited Formulacje przeciwciała t1h
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
US20110158987A1 (en) * 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
BR112012033457A2 (pt) * 2010-07-02 2017-04-04 Medimmune Llc formulações de anticorpo.
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
JP6693872B2 (ja) * 2013-07-25 2020-05-13 シトムクス セラピューティクス，インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
CN104341505A (zh) * 2013-07-29 2015-02-11 西藏海思科药业集团股份有限公司 对蒙古人种和高加索人种低免疫原性的、抗egfr的人鼠嵌合抗体
WO2015038984A2 (en) * 2013-09-12 2015-03-19 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
US20170231995A1 (en) 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
CA2944085C (en) * 2014-09-16 2018-04-10 Ease Charm Limited Anti-egfr antibody and uses of same
CN105435221B (zh) * 2014-09-22 2021-09-28 正大天晴药业集团股份有限公司 一种针对血管内皮生长因子的人源化抗体的药物组合物
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
US10717783B2 (en) * 2014-12-22 2020-07-21 Zeren Gao Bispecific tetravalent antibodies and methods of making and using thereof
US12428483B2 (en) 2014-12-22 2025-09-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
KR101776879B1 (ko) * 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
WO2017077507A1 (en) 2015-11-06 2017-05-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
MX2019007824A (es) * 2016-12-28 2019-09-09 Japan Chem Res Preparacion liofilizada.
BR112019021723A2 (pt) * 2017-04-18 2021-06-29 Dr. Reddy's Laboratories Limited formulação de anticorpo líquida estável, anticorpo na formulação, formulação líquida estável de anticorpo anti-il6r, formulação líquida estável de tocilizumab em sistema de tampão de fosfato-aminoácido, e, formulação líquida estável de tocilizumab
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
WO2019232478A1 (en) 2018-06-01 2019-12-05 Rakuten Medical, Inc. Phthalocyanine dye conjugate compositions
CN110960490A (zh) * 2018-09-28 2020-04-07 江苏恒瑞医药股份有限公司 一种抗egfr抗体偶联药物组合物及其用途
JP7542543B2 (ja) 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
US12704501B2 (en) 2019-03-29 2026-08-11 Rakuten Medical, Inc. Methods for photoimmunotherapy and related biomarkers
JP2022545312A (ja) 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
US20230220105A1 (en) * 2019-06-06 2023-07-13 Janux Therapeutics, Inc. Tumor activated t cell engagers and methods of use thereof
CU20190104A7 (es) * 2019-12-17 2021-08-06 Ct Inmunologia Molecular Formulación estable del anticuerpo nimotuzumab
AU2021326469C1 (en) 2020-08-11 2026-04-30 Janux Therapeutics, Inc. Cleavable linker compositions and methods
EP4259193A4 (en) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
EP4259200A1 (en) * 2020-12-11 2023-10-18 Boehringer Ingelheim International GmbH Formulation for multi-purpose application
AU2022357570A1 (en) * 2021-10-03 2024-04-11 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof
CN119855620A (zh) * 2022-09-16 2025-04-18 国立研究开发法人量子科学技术研究开发机构 放射性医药组合物的中间体的制造方法、放射性医药组合物的中间体的纯化用试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62158160A (ja) * 1985-12-27 1987-07-14 堺化学工業株式会社 成形触媒及び接触反応方法
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6695940B2 (en) * 2001-04-05 2004-02-24 Alan D. Devoe Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
ES2387809T3 (es) * 2004-03-19 2012-10-02 Imclone Llc Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
WO2007095337A2 (en) * 2006-02-15 2007-08-23 Imclone Systems Incorporated Antibody formulation

Also Published As

Publication number Publication date
EP2029163A2 (en) 2009-03-04
TNSN08511A1 (en) 2010-04-14
AU2007260769A1 (en) 2007-12-21
NO20085131L (no) 2009-03-13
KR20090021298A (ko) 2009-03-02
EA200870538A1 (ru) 2009-04-28
MA30515B1 (fr) 2009-06-01
US20100158925A1 (en) 2010-06-24
ECSP088962A (es) 2009-01-30
CR10493A (es) 2009-02-26
CN101466404A (zh) 2009-06-24
EP2029163A4 (en) 2010-08-11
JP2009540015A (ja) 2009-11-19
CA2654794A1 (en) 2007-12-21
WO2007147001A3 (en) 2008-07-10
MX2008015852A (es) 2009-02-23
WO2007147001A2 (en) 2007-12-21
IL195794A0 (en) 2011-08-01
ZA200810456B (en) 2009-12-30

Similar Documents

Publication Publication Date Title
ECSP088962A (es) Nuevos herbicidas
PE20141159A1 (es) Metodos para tratar o prevenir trastornos relacionados con el colesterol
BRPI0514340A (pt) formulações de estabilização
EA200970880A1 (ru) Стабильные композиции на основе антител
BRPI0818765A8 (pt) Polipeptídeo, anticorpo ou seu fragmento de ligação de antígeno, polinucleotídeo, célula hospedeira, vetor, composição, uso e método para produzir polipeptídeo
CL2020002012A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032)
EA201001204A1 (ru) Методы и композиции, в которых применяют слитые полипептиды klotho-fgf
BR112012018951B8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
BRPI0613382A8 (pt) anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
ECSP10010697A (es) Inhibidores de dpp-iv para uso en el tratamiento de nafld
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
RU2013137740A (ru) Жидкая композиция, содержащая антитело высокой концентрации
TW200621804A (en) Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer
EA201100072A1 (ru) Новые композиции и способы
BRPI0516408B8 (pt) derivados de estilbeno e seu uso para ligação e formação de imagem de placas de amilóide
BR112015009037A2 (pt) composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
BR112014009785A8 (pt) método para tratar ou reduzir efp
EA201000879A1 (ru) Производные пиразола и их применение в качестве ингибиторов циклинзависимости киназ
EA201001749A1 (ru) Способ лечения недифференцированного артрита
GT200600115A (es) Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal
BRPI0720230A2 (pt) Uso de uma formulação nutricional oralmente administrável, formulação nutricional, método para tratar um distúrbio desenvolvimental penetrante, e, composição
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
BRPI0607084A2 (pt) uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: IMCLONE LLC (US)

Free format text: NOME ALTERADO DE: IMCLONE SYSTEMS INCORPORATED

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 5A ANUIDADE.